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ABSTRACT  
We evaluated the efficacy and safety of short-term fully closed-loop insulin delivery using faster 
versus standard insulin aspart in type 2 diabetes. Fifteen adults with insulin-treated type 2 diabetes 
underwent 22 hours of closed-loop insulin delivery with either faster or standard insulin aspart in a 
double-blind randomised crossover design. Basal-bolus regimen was replaced by model predictive 
control algorithm-directed insulin delivery based on sensor glucose levels. The primary outcome was 
time with plasma glucose in target range (5.6-10.0mmol/l) and did not differ between treatments 
(mean difference [95%CI] -3.3% [8.2;1.7], p=0.17). Mean glucose and glucose variability were 
comparable, as was time spent below and above target range. Hypoglycaemia (<3.5mmol/l) occurred 
once with faster insulin aspart and twice with standard insulin aspart. Mean total insulin dose was 
higher with faster insulin aspart (mean difference [95%CI] 3.7U [0.7;6.8], p=0.021). No episodes of 
severe hypoglycaemia or other serious adverse events occurred. In conclusion, short-term fully 
closed-loop in type 2 diabetes may require higher dose of faster insulin aspart compared to standard 
insulin aspart to achieve comparable glucose control.  
Trial registration:  NCT01774565 
 
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dom.13861
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 INTRODUCTION 
Faster insulin aspart is a novel formulation of conventional insulin aspart that includes niacinamide for 
quicker absorption following subcutaneous administration
1
, resulting in faster pharmacokinetic and 
pharmacodynamic profiles
2-4
. It was developed to more closely match physiological insulin profile with 
the goal of improving postprandial glucose control.  
The more favourable pharmacokinetic and pharmacodynamic properties of faster insulin aspart 
compared to standard insulin aspart were substantiated in clinical studies enrolling people with type 1 
and type 2 diabetes
2,5
. 
Closed-loop insulin delivery is an emerging therapeutic modality that titrates insulin in response to 
sensor glucose levels and has been shown to improve glucose control across populations and ages 
of subjects with type 1 to type 2 diabetes
6-10
. In a post-hoc analysis of an outpatient hybrid closed-loop 
study, a shorter time to peak to insulin levels was associated with improved glucose control
11
 
supporting the general notion that faster insulin absorption such as that presented by faster insulin 
aspart due to its more favourable pharmacokinetic profile can further improve the performance of 
closed-loop systems. The objective of this pilot study was to evaluate whether short-term use of fully 
closed-loop insulin delivery using faster versus standard insulin aspart in insulin-treated adults with 
type 2 diabetes improves glucose control. 
 
RESEARCH DESIGN AND METHODS 
Study design and procedures 
This was a randomized, single-centre, double-blind, two-period, crossover study in 15 adults with 
insulin-treated type 2 diabetes. The protocol was approved by the local Ethics Committee and 
Swissmedic, and conducted from April 10, 2018 to September 9, 2018 in accordance with Good 
Clinical Practice Guidelines and the Declaration of Helsinki. All participants gave written informed 
consent prior to commencing study procedures.  
Participants were recruited from the outpatient diabetes clinic at University Hospital Bern. Inclusion 
criteria were age≥18years, type 2 diabetes treated with basal-bolus insulin for ≥3months, and 
haemoglobin A1c≤11.0% (97mmol/mol). Exclusion criteria were type 1 diabetes, pregnancy or 
breastfeeding, and incapacity to give informed consent or follow study procedures.  
Participants were assigned to receive either faster insulin aspart followed by standard insulin aspart, 
or vice versa, using computer generated block randomisation (1:1). They attended the study centre at 
1830 for 22hours (Figure S1, Supplemental Appendix) twice, separated by a 1-2 week washout, and 
on each occasion underwent identical procedures. The Freestyle Navigator II continuous glucose 
monitor (Abbott Diabetes Care, Alameda, CA, USA) was inserted 1-4 days before each visit. Long-
acting insulin dose was halved if injected in the morning or withheld if injected in the evening prior to 
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study visits. All non-insulin agents were continued except for sulphonylurea medication. After arrival, a 
cannula was inserted in the abdomen for subcutaneous insulin delivery (Fiasp or Novorapid, Novo 
Nordisk, Bagsvaerd, Denmark) by a study pump (Dana R Diabecare, Sooil, Seoul, South Korea). The 
closed-loop algorithm comprised a model predictive controller (version 0.3.70) residing on a tablet 
device (Dell Latitude 10 Tablet, Dell, TX, USA) linked by USB to the continuous glucose receiver and 
by Bluetooth to the pump (Figure S2). We initialized the system using the participant’s weight and 
total daily insulin dose, which were kept identical for both visits. The algorithm did not account for 
background basal insulin and no adaptation was made to factor in the pharmacokinetic differences of 
the two insulin formulations. Closed-loop glucose control without announcement or bolusing for meals 
was started and continued until 1700 the next day.  
After start of closed-loop, participants were served a sandwich and went to bed afterward. The next 
morning, a peripheral intravenous cannula was inserted for regular plasma glucose sampling every 
15min from 0700-1000 and 1200-1500, every 30min from 1000-1200 and 1500-1700, using the 
Biosen C-Line Analyser (EKF Diagnostics, Barleben, Germany). Standardized meals were consumed 
at 0700 (53.7±8.8g carbohydrates) and 1200 (72.8±17.5g carbohydrates), matched on both study 
visits. Decaffeinated sugar-free tea or water were served ad libitum during the test. Subjects remained 
largely sedentary during visits except for a 20min-walk 3h after breakfast. Participant’s insulin therapy 
was resumed at the end of the study visit before discharge. 
 
Study outcomes and statistical analysis 
Participants and the study staff were blind to the study treatment until after the final data analysis. 
Due to the pilot nature of the study, no formal power calculation was applied. We aimed to analyse 15 
participants with complete data. The primary endpoint was the percentage of time with plasma 
glucose between 5.6 to 10.0mmol/l from 0700 to 1700 (10h), in line with previous studies in adults 
with type 2 diabetes using the same fully closed-loop insulin delivery system
12,13
. Other endpoints are 
listed in Table S1. Treatments were compared using linear mixed-effect models with treatment as 
fixed, and period and subject as random effects. P-values<0.05 (two-sided) were considered 
statistically significant. Statistical analyses were performed using SPSS, Version 23 (IBM Software, 
Hampshire, UK). 
RESULTS 
Out of 26 invitees, 20 consented and 15 were included in the analysis (Figure S3). Baseline 
characteristics and diabetes therapy are summarized in Table S2 and Table S3. 
Primary and secondary endpoints are shown in Table 1. The proportion of time with plasma glucose 
in target range did not differ between the treatments (67.7±16.3 vs. 70.9±17.3%, mean difference 
[95%CI] -3.3% [-8.2;1.7], p=0.17). Mean glucose and glucose variability were comparable as was time 
spent below and above target. The 2h-postprandial glucose increment was not different after 
breakfast (p=0.78) but was significantly higher after lunch with faster insulin aspart (p=0.047). Sensor-
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved.
based outcomes over the 10h study period and secondary outcomes over the entire study period are 
shown in Table S4 and Table S5. Insulin dose was significantly higher with faster insulin aspart 
(31.9±22.6 vs. 28.2±20.1U, mean difference [95%CI] 3.7U [0.7;6.8], p=0.021). Glucose and insulin 
delivery profiles are illustrated in Figure 1. One hypoglycaemic event (plasma glucose<3.5mmol/l) 
occurred with faster insulin aspart and two with standard insulin aspart, which were treated with 15g 
of rapid-acting oral carbohydrates as per protocol, without the need for intravenous dextrose. 
Hypoglycaemic events occurred in the late postprandial period before lunch in all participants. One 
subject experienced twice capillary blood glucose level>20mmol/l without ketonemia after dinner. No 
severe hypoglycaemia or other serious adverse events occurred (Table S6). 
CONCLUSIONS 
The present pilot study demonstrated that short-term fully automated-closed loop in type 2 diabetes 
using faster and standard insulin aspart resulted in comparable glucose control but required higher 
dose of faster insulin aspart to achieve such outcomes. No differences in hypoglycaemia were 
observed.  
 
To our knowledge, this is the first study assessing the incremental benefit of faster insulin aspart 
during short-term use of fully closed-loop insulin delivery in type 2 diabetes. Previous trials that 
evaluated the use of faster versus standard insulin aspart with injection and pump therapy reported no 
significant differences for overall glycaemic control between the two insulin formulations
14-18
. Several 
factors may explain the lack of improved glucose control during short-term application of fully closed-
loop despite the more favourable pharmacokinetic and pharmacodynamic profile of faster insulin 
aspart
2
 that has also recently been confirmed in adults with type 2 diabetes
5
. First, the adaptation of 
the fully closed-loop control algorithm to higher insulin doses needed with faster insulin aspart, which 
may in part be related to the left-shift of the pharmacokinetic profile, may take longer and the short 
study duration was not permissive for this to happen. Second, the difference in the onset of action, 
8.9min earlier
5
, is modest, especially in the light of the considerable intra-patient variability in insulin 
absorption
19
, thereby diminishing potential benefits. Thus, further longer and adequately powered 
studies are warranted. 
 
The previously reported superior postprandial glucose control of faster insulin aspart compared to 
standard insulin aspart when administered as a meal bolus during pump or injection therapy in type 1 
and type 2 diabetes
14,16,18
 does not concur with our findings. We observed postprandial glycaemic 
increments that were comparable after breakfast and even higher with faster insulin aspart after 
lunch. The dynamic setting of fully closed-loop, without administration of predetermined meal bolus, 
may have accounted for the distinct findings. Hybrid closed-loop which applies meal announcement or 
bolus delivery is more comparable with conventional pump or injection therapy than fully closed-loop 
in terms of postprandial glucose control. Further studies are required to elucidate the role of faster 
insulin aspart for meal-time glucose control during fully and hybrid closed-loop control and dissect the 
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causes of the discord between our findings observed during fully closed-loop glucose control versus 
those observed during conventional pump or injection therapy.  
 
The occurrence of hypoglycaemia did not differ between the two treatments. All hypoglycaemic 
events occurred in participants treated with insulin degludec. Residual background long-acting insulin 
levels could have been contributory as these were not accounted for during initialization of closed-
loop. Thus, consideration of exposure to background insulin may be warranted in patients being 
treated with ultra-long acting insulin. 
 
The strengths of our study include the novelty of the research question, the double-blind randomized 
crossover design and the standardized setting. Limitations include the short study duration, small 
sample size, and a single-centre study design. Findings of the present pilot study may inform the 
design of future studies assessing the performance of closed-loop glucose control using different 
insulin formulations. 
 
In conclusion, short-term fully automated closed-loop insulin delivery using faster insulin aspart in 
adults with type 2 diabetes achieved comparable glucose control with a higher insulin dose compared 
to standard insulin aspart. Further research is needed to assess the benefits of faster insulin aspart 
for closed-loop insulin therapy in different populations.  
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Table 1. Performance of fully closed-loop insulin delivery using faster insulin aspart (FA) and 
standard insulin aspart (A) over the 10h-period (from breakfast at 0700 to discharge at 1700) 
based on plasma glucose.  
  
 
Closed-loop 
with FA 
(n=15) 
Closed-loop 
with A 
(n=15) 
Paired 
difference* or 
paired ratio
†
 
(FA-A) [95% CI] 
(n=15) 
p 
value 
Time spent at glucose levels (%) 
    
                  5.6 to 10.0 mmol/l 67.7±16.3 70.9±17.3 -3.3 [-8.2;1.7] 0.17 
                  >10.0 mmol/l 22.1±18.2 20.3±15.9 1.8 [-4.2;7.8] 0.53 
                  <5.6 mmol/l 10.3±13.4 8.8±11.2 1.5 [-2.0;5.1] 0.37 
                  <3.9 mmol/l 0.0 (0.0-0.0) 0.0 (0.0-5.2) 0.62 [0.37;1.05]
†
 0.072 
Mean glucose (mmol/l) 8.5±1.3 8.3±1.0 0.2 [-0.2;0.6] 0.38 
Standard deviation of glucose (mmol/l) 2.0±0.7 2.0±0.7 -0.1 [-0.4;0.3] 0.69 
Coefficient of variation of glucose (%) 23.0±8.6 24.5±8.6 -1.5 [-4.0;1.0] 0.22 
Hypoglycaemic events (<3.5 mmol/l) 1 [7] 2 [13] -  1.00 
2h breakfast glucose increment (mmol/l) 3.8±1.6 3.9±2.2 -0.1 [-0.9;0.8] 0.78 
2h breakfast insulin dose (U) 13.4±11.0 11.8±8.6 1.6 [-0.8;4.0] 0.18 
2h lunch glucose increment (mmol/l) 3.7±3.2 2.8±2.6 0.8 [0.0;1.6] 0.047 
2h lunch insulin dose (U) 3.7±2.6 3.2±2.3 0.5 [-1.4;2.5] 0.56 
10h insulin dose (U) 31.9±22.6 28.2±20.1 3.7 [0.7;6.8] 0.021 
Data are mean±SD, median (IQR), mean [95% CI] or n [%]. 2h glucose increment, rise in glucose 
concentration from start of the meal until two hours later; 2h insulin dose, amount of insulin infused 
from start of the meal until two hours later. 10h insulin dose, amount of insulin delivered by the fully 
closed-loop system over the 10hour period. *Unless specified otherwise, data are normally distributed 
and presented as mean difference of closed-loop with FA minus closed-loop with A, with 95% CI for 
mean; a positive value indicates that the measurement was higher in the closed-loop period with FA 
than in the closed-loop period with A. 
†
Non-normally distributed data are presented as ratio of closed-
loop with FA data over closed-loop with A data, with 95% CI for ratio; a value greater than unity 
indicates that the measurement was higher in the closed-loop period with FA than in the closed-loop 
period with A. 
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Figure caption 
Figure 1. (Panel A) Plasma glucose and (Panel B) sensor glucose concentration during fully closed-
loop insulin delivery with faster insulin aspart (red) and standard insulin aspart (grey) (lines indicate 
median, shaded areas indicate interquartile ranges). (Panel C) Algorithm-directed insulin delivery (line 
indicates median, shaded area indicates interquartile ranges). Time origin represents breakfast time. 
N=15.  
 
  
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved.
REFERENCES  
1. Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H. Faster-acting insulin aspart: 
earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic 
effects than insulin aspart. Diabetes Obes Metab. 2015;17(7):682-688. 
2. Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A Pooled Analysis of Clinical Pharmacology 
Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting 
Insulin Aspart in Adults with Type 1 Diabetes. Clin Pharmacokinet. 2017;56(5):551-559. 
3. Heise T, Zijlstra E, Nosek L, Rikte T, Haahr H. Pharmacological properties of faster-acting 
insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous 
subcutaneous insulin infusion: A randomized, double-blind, crossover trial. Diabetes Obes 
Metab. 2017;19(2):208-215. 
4. Bode BW, Johnson JA, Hyveled L, Tamer SC, Demissie M. Improved Postprandial Glycemic 
Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous 
Subcutaneous Insulin Infusion. Diabetes Technol Ther. 2017;19(1):25-33. 
5. Pieber TR, Svehlikova E, Brunner M, Halberg IB, Thomsen KMD, Haahr H. Fast-acting insulin 
aspart in subjects with type 2 diabetes: Earlier onset and greater initial exposure and 
glucose-lowering effect compared with insulin aspart. Diabetes Obes Metab. 2019. 
6. Bally L, Thabit H, Kojzar H, et al. Day-and-night glycaemic control with closed-loop insulin 
delivery versus conventional insulin pump therapy in free-living adults with well controlled 
type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes Endocrinol. 
2017;5(4):261-270. 
7. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in 
Women with Type 1 Diabetes. N Engl J Med. 2016;375(7):644-654. 
8. Tauschmann M, Thabit H, Bally L, et al. Closed-loop insulin delivery in suboptimally 
controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 
2018;392(10155):1321-1329. 
9. Bally L, Thabit H, Hartnell S, et al. Closed-Loop Insulin Delivery for Glycemic Control in 
Noncritical Care. N Engl J Med. 2018;379(6):547-556. 
10. Thabit H, Tauschmann M, Allen JM, et al. Home use of an artificial beta cell in type 1 
diabetes. N Engl J Med. 2015;373(22):2129-2140. 
11. Ruan Y, Thabit H, Leelarathna L, et al. Faster insulin action is associated with improved 
glycaemic outcomes during closed-loop insulin delivery and sensor-augmented pump 
therapy in adults with type 1 diabetes. Diabetes Obes Metab. 2017;19(10):1485-1489. 
12. Bally L, Gubler P, Thabit H, et al. Fully closed-loop insulin delivery improves glucose control 
of inpatients with type 2 diabetes receiving hemodialysis. Kidney International. 2019. 
13. Boughton CK, Bally L, Martignoni F, et al. Fully closed-loop insulin delivery in inpatients 
receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet 
Diabetes Endocrinol. 2019;7(5):368-377. 
14. Russell-Jones D, Bode BW, De Block C, et al. Fast-Acting Insulin Aspart Improves Glycemic 
Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, 
Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). Diabetes 
Care. 2017;40(7):943-950. 
15. Mathieu C, Bode BW, Franek E, et al. Efficacy and safety of fast-acting insulin aspart in 
comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-
to-target, phase III trial. Diabetes Obes Metab. 2018;20(5):1148-1155. 
16. Bowering K, Case C, Harvey J, et al. Faster Aspart Versus Insulin Aspart as Part of a Basal-
Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diabetes Care. 
2017;40(7):951-957. 
17. Rodbard HW, Tripathy D, Vidrio Velázquez M, Demissie M, Tamer SC, Piletič M. Adding fast-
acting insulin aspart to basal insulin significantly improved glycaemic control in patients with 
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved.
type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3). Diabetes Obes 
Metab. 2017;19(10):1389-1396. 
18. Klonoff DC, Evans ML, Lane W, et al. A randomized, multicentre trial evaluating the efficacy 
and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults 
with type 1 diabetes (onset 5). Diabetes Obes Metab. 2018. doi: 10.1111/dom.13610. 
19. Haidar A, Elleri D, Kumareswaran K, et al. Pharmacokinetics of insulin aspart in pump-treated 
subjects with type 1 diabetes: reproducibility and effect of age, weight, and duration of 
diabetes. Diabetes Care. 2013;36(10):e173-174. 
 
A
cc
ep
te
d 
A
rti
cl
e
This article is protected by copyright. All rights reserved.
